SEHK:1681Pharmaceuticals
Consun Pharmaceutical Group (SEHK:1681) Earnings Growth And 31.5% Margins Challenge Valuation Skeptics
Consun Pharmaceutical Group (SEHK:1681) opened FY 2025 with first half revenue of C¥1.57b and basic EPS of C¥0.59, set against trailing twelve month revenue of C¥3.42b and EPS of C¥1.27 that reflect earnings growth of 18.4% over the past year. The company has seen revenue move from C¥2.97b to C¥3.42b on a trailing basis, while EPS has gone from C¥1.11 to C¥1.27, supported by a trailing net profit margin of 31.5% that edges above last year’s 30.7%. This keeps profitability squarely in focus...